Skip to main content
SpringerLink
Log in

Resistance to antiplatelet therapy

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Cardiovascular mortality continues to be high and events continue to occur in patients taking antiplatelet medications. Aspirin and clopidogrel have become integral parts of management in patients with coronary artery disease and after percutaneous angioplasty. However, the platelet responses to aspirin and clopidogrel are not uniform. Diminished or lack of response to these agents has been termed aspirin resistance and clopidogrel resistance. These phenomena have tremendous clinical significance as together they may occur in more than 50% of all patients on chronic therapy with aspirin or clopidogrel. Postulated mechanisms of aspirin and clopidogrel resistance include alterations in genetic, pharmacokinetic, and platelet properties. There is a dearth of information in regard to their clinical significance, methods to test them, and strategies to treat them. Further research is necessary in these areas to identify these patients and treat them appropriately.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308:81–106.

    Google Scholar 

  2. Yusuf S, Zhao F, Mehta SR, et al., for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494–502.

    Article  PubMed  CAS  Google Scholar 

  3. Gum PA, Kottke-Marchant K, Welsh PA, et al.: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961–965. The first prospective study of aspirin resistance in patients with CAD with a 2-year follow-up, based on platelet aggregometry.

    Article  PubMed  CAS  Google Scholar 

  4. Matetzky S, Shenkman B, Guetta V, et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171–3175. A 6-month follow-up of clopidogrel-resistant patients and the only outcome study performed in this population.

    Article  PubMed  CAS  Google Scholar 

  5. Cattaneo M: Aspirin and clopidogrel. efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004, 24:1–8.

    Article  CAS  Google Scholar 

  6. Chen WH, Lee PY, Ng W, et al.: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pre-treatment. J Am Coll Cardiol 2004, 43:1122–1126.

    Article  PubMed  CAS  Google Scholar 

  7. Wang JC, Aucoin-Barry D, Manuelian D, et al.: Incidence of aspirin nonresponsiveness using the ultegra rapid platelet function assay-ASA. Am J Cardiol 2003, 92:1492–1494.

    Article  PubMed  Google Scholar 

  8. Chakroun T, Gerotziafas G, Robert F, et al.: In vitro aspirin resistance detected by PFA-100 TM closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004, 124:80–85.

    Article  PubMed  CAS  Google Scholar 

  9. Andersen K, Hurlen M, Arnesen H, Seljeflot I: Aspirin nonresponsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2003, 108:37–42.

    Article  CAS  Google Scholar 

  10. Grundmann K, Jaschonek K, Kleine B, et al.: Aspirin non-responders status in patients with recurrent cerebral ischemic attacks. J Neurol 2003, 250:63–66.

    Article  PubMed  CAS  Google Scholar 

  11. Roller RE, Dorr A, Ulrich S, Pilger E: Effect of aspirin treatment in patients with peripheral arterial disease monitors with the platelet function analyser PFA-100. Blood Coagul Fibrinolysis 2002, 13:277–281.

    Article  PubMed  CAS  Google Scholar 

  12. Christiaens L, Macchi L, Herpin D, et al.: Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res 2003, 108:115–119.

    Article  CAS  Google Scholar 

  13. Macchi L, Christiaens L, Brabant S, et al.: Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GPIIIa) polymorphism but not with C807T (GPIa/IIa) and C-5T Kozak (GPIb_) polymorphisms. J Am Coll Cardiol 2003, 42:1115–1119.

    Article  PubMed  CAS  Google Scholar 

  14. Eikelboom JW, Hirsh J, Weitz JI, et al.: Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105:1650–1655. The largest prospective analysis of aspirin resistance done in patients in the HOPE trial, based on quartiles of urine thromboxane levels.

    Article  PubMed  CAS  Google Scholar 

  15. Helgason CM, Bolin KM, Hoff JA, et al.: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994, 25:2331–2336.

    PubMed  CAS  Google Scholar 

  16. Grotemeyer KH, Scharafinski HW, Husstedt IW: Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993, 71:397–403.

    Article  PubMed  CAS  Google Scholar 

  17. Gum PA, Kottke-Marchant K, Topol EJ, et al.: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001, 88:230–235.

    Article  PubMed  CAS  Google Scholar 

  18. Mueller MR, Salat A, Stangl P, et al.: Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997, 78:1003–1007.

    PubMed  CAS  Google Scholar 

  19. Weber AA, Zimmermann K, Meyer-Kirchrath J, et al.: Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999, 353:900.

    Article  PubMed  CAS  Google Scholar 

  20. Zimmerman N, Kim U, Kienzle P, et al.: Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003, 108:542–547.

    Article  CAS  Google Scholar 

  21. Karim S, Habib A, Levy-Toledano S, Maclouf J: Cyclooxygenase-1 and-2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 1996, 271:12042–12048.

    Article  PubMed  CAS  Google Scholar 

  22. Bustos M, Coffman TM, Saadi S, Platt JL: Modulation of eicosanoid metabolism in endothelial cells in a xenograt model: role of cyclooxygenase-2. J Clin Invest 1997, 100:1150.

    Article  PubMed  CAS  Google Scholar 

  23. Cipollone F, Patrignani P, Greco A, et al.: Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997, 96:1109–1116.

    PubMed  CAS  Google Scholar 

  24. Halushka MK, Walker LP, Halushka PV: Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003, 78:122–130.

    Article  CAS  Google Scholar 

  25. Cipollone F, Toniato E, Martinotti S, Identification of New Elements of Plaque Stability (INES) Study Group: A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004, 291:2221–2228. This study describes the clinical significance of a recently identified COX-2 polymorphism.

    Article  PubMed  CAS  Google Scholar 

  26. Weiss ET, Bray PF, Tayback M, et al.: A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996, 334:1090–1094.

    Article  PubMed  CAS  Google Scholar 

  27. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A: Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001, 104:2666–2672.

    PubMed  CAS  Google Scholar 

  28. Dabaghi SF, Kamat SG, Kleiman NS, et al.: Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. Am J Cardiol 1994, 74:720–723.

    Article  PubMed  CAS  Google Scholar 

  29. Catella-Lawson F, Reilly MP, Kapoor SC, et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809–1817.

    Article  PubMed  CAS  Google Scholar 

  30. Ray WA, Stein CM, Hall K, et al.: Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002, 359:118–123.

    Article  PubMed  CAS  Google Scholar 

  31. Rocca B, Secchiero P, Ciabattoni G, et al.: Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002, 99:7634–639.

    Article  PubMed  CAS  Google Scholar 

  32. Kawasaki T, Ozeki Y, Igawa T, Kambayashi J: Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000, 31:591–595.

    PubMed  CAS  Google Scholar 

  33. Macchi L, Christiaens L, Brabant S: Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002, 107:45–49.

    Article  PubMed  CAS  Google Scholar 

  34. Valles J, Santos MT, Aznar J, et al.: Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998, 97:350–355.

    PubMed  CAS  Google Scholar 

  35. Cipollone F, Ciabattoni G, Patrignani P, et al.: Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000, 102:1007–1013.

    PubMed  CAS  Google Scholar 

  36. Pratico` D, Smyth EM, Violi F, et al.: Local amplification of platelet function by 8-epi-prostaglandin F2a is not mediated by thromboxane receptor isoforms. J Biol Chem 1996, 271:14916–14924.

    Article  PubMed  CAS  Google Scholar 

  37. Geiger J, Brich J, Honig-Liedl P, et al.: Specific impairment of human platelet P2Yac ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999, 19:2007–2011.

    PubMed  CAS  Google Scholar 

  38. Savi P, Pereillo JM, Uzabiaga MF, et al.: Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000, 84:891–896.

    PubMed  CAS  Google Scholar 

  39. Jaremo P, Lindahl TL, Gransson SB, et al.: Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002, 252:233–238.

    Article  PubMed  CAS  Google Scholar 

  40. Gurbel PA, Bliden KP, Hiatt BL, et al.: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107:2908–2913. This study is one of the first reports on clopidogrel resistance.

    Article  PubMed  Google Scholar 

  41. Lepantalo A, Virtanen KS, Heikkila J, et al.: Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 2004 Mar, 25:476–483.

    Article  PubMed  CAS  Google Scholar 

  42. Muller I, Besta F, Schulz C, et al.: Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003, 89:783–787.

    PubMed  CAS  Google Scholar 

  43. Lau WC, Gurbel PA, Watkins PB, et al.: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004, 109:166–171.

    Article  PubMed  CAS  Google Scholar 

  44. Grossmann R, Sokolova O, Schnurr A, et al.: Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004, 92:1201–1206.

    PubMed  CAS  Google Scholar 

  45. Serebruany VL, Steinhubl SR, Berger PB, et al.: Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005, 45:246–251.

    Article  PubMed  CAS  Google Scholar 

  46. Lau WC, Waskell LA, Watkins PB, et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003, 107:32–37.

    Article  PubMed  CAS  Google Scholar 

  47. Fontana P, Dupont A, Gandrille S, et al.: Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003, 108:989–995.

    Article  PubMed  CAS  Google Scholar 

  48. Steinhubl SR, Darrah S, Brennan D, et al.: Optimal duration of pretreatment with clopidogrel prior to PCI: data from the CREDO trial. Circulation 2003, 108(Suppl I):I1742.

    Google Scholar 

  49. Kandzari DE, Berger PB, Kastrati A, ISAR-REACT Study Investigators: Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004, 44:2133–2136.

    Article  PubMed  CAS  Google Scholar 

  50. Angiolillo DJ, Fernandez-Ortiz A, et al.: Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005, 115:101–108.

    Article  PubMed  CAS  Google Scholar 

  51. Saw J, Steinhubl SR, Berger PB, Clopidogrel for the Reduction of Events During Observation Investigators: Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003, 108:921–924.

    Article  PubMed  CAS  Google Scholar 

  52. Lev EI, Bray PF, Kleiman NS, et al.: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: a role for dual drug resistance? J Am Coll Cardiol 2005, 45(Suppl A):86A.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Baylor College of Medicine, 6565 Fannin, MS F1090, 77030, Houston, TX, USA

    Neal S. Kleiman MD

Authors
  1. Sasidhar Guthikonda MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eli I. Lev MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neal S. Kleiman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guthikonda, S., Lev, E.I. & Kleiman, N.S. Resistance to antiplatelet therapy. Curr Cardiol Rep 7, 242–248 (2005). https://doi.org/10.1007/s11886-005-0044-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-005-0044-0

Keywords

Search

Navigation